Form 4: OrbiMed Advisors Reports Adicet Bio Stock Transactions

OrbiMed Advisors LLC and affiliated entities have reported significant transactions involving Adicet Bio, Inc. (ACET) common stock.

Summary

• OrbiMed Advisors LLC, along with several affiliated entities including OrbiMed Capital GP V LLC, OrbiMed Capital GP VI LLC, OrbiMed Genesis GP LLC, OrbiMed Advisors Israel II Ltd, OrbiMed Israel GP II, L.P., OrbiMed Israel GP Ltd., and OrbiMed Israel BioFund GP Limited Partnership, have filed a Form 4 detailing changes in beneficial ownership of Adicet Bio, Inc. (ACET) common stock.
• The filings indicate multiple transactions of common stock occurring on April 7th and April 8th, 2026.
• These transactions include acquisitions and dispositions of common stock, resulting in varying levels of beneficial ownership reported by the different OrbiMed entities.
• Specific details of acquired and disposed securities, along with the resulting beneficial ownership amounts, are provided in the filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine changes in beneficial ownership by a major investor and does not contain new strategic information or financial performance data.

Future Outlook

No specific forward-looking statements or guidance were provided in this Form 4 filing.

Management Comments

• Each of the reporting entities disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of their pecuniary interest therein, if any.
• The report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for significant shareholders and insiders, providing transparency into stock ownership changes. This filing details routine adjustments in beneficial ownership by a major investment firm, OrbiMed Advisors, in Adicet Bio, Inc.

Stakeholder Impact

• Shareholders: Provides transparency into the holdings of a significant investor, OrbiMed Advisors, which can inform investment decisions.
• Management: The filing details transactions by entities associated with OrbiMed, a significant stakeholder, which is a standard disclosure requirement.

Key Dates

Keywords

Form 4, SEC Filing, Beneficial Ownership, Stock Transaction, Adicet Bio, ACET, OrbiMed Advisors, Insider Trading